Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 543

1.

50 years forward: mechanisms of hyperglycaemia-driven diabetic complications.

Russell ND, Cooper ME.

Diabetologia. 2015 Apr 24. [Epub ahead of print]

PMID:
25906755
2.

Replication of 13q31.1 association in nonsyndromic cleft lip with cleft palate in Europeans.

Jia Z, Leslie EJ, Cooper ME, Butali A, Standley J, Rigdon J, Suzuki S, Gongorjav A, Shonkhuuz TE, Natsume N, Shi B, Marazita ML, Murray JC.

Am J Med Genet A. 2015 May;167(5):1054-60. doi: 10.1002/ajmg.a.36912. Epub 2015 Mar 18.

PMID:
25786657
3.

AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy.

Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Hypertension. 2015 May;65(5):1073-81. doi: 10.1161/HYPERTENSIONAHA.115.05204. Epub 2015 Mar 16.

PMID:
25776077
4.

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.

Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL.

Am J Nephrol. 2014;40(6):572-81. doi: 10.1159/000371497. Epub 2015 Jan 10.

PMID:
25591469
5.

ACE2 deficiency shifts energy metabolism towards glucose utilization.

Bernardi S, Tikellis C, Candido R, Tsorotes D, Pickering RJ, Bossi F, Carretta R, Fabris B, Cooper ME, Thomas MC.

Metabolism. 2015 Mar;64(3):406-15. doi: 10.1016/j.metabol.2014.11.004. Epub 2014 Nov 20.

PMID:
25484288
6.

Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia.

Bello NA, Pfeffer MA, Skali H, McGill JB, Rossert J, Olson KA, Weinrauch L, Cooper ME, de Zeeuw D, Rossing P, McMurray JJ, Solomon SD.

BMJ Open Diabetes Res Care. 2014 Apr 6;2(1):e000011. doi: 10.1136/bmjdrc-2013-000011. eCollection 2014.

7.

Nox-4 and progressive kidney disease.

Thallas-Bonke V, Jandeleit-Dahm KA, Cooper ME.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):74-80. doi: 10.1097/MNH.0000000000000082.

PMID:
25402870
8.

Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy.

Thallas-Bonke V, Jha JC, Gray SP, Barit D, Haller H, Schmidt HH, Coughlan MT, Cooper ME, Forbes JM, Jandeleit-Dahm KA.

Physiol Rep. 2014 Nov 3;2(11). pii: e12192. doi: 10.14814/phy2.12192. Print 2014 Nov 1.

9.

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group.

N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19.

10.

Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes.

Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, Williams B, Chalmers J; ADVANCE Collaborative group.

Diabetologia. 2014 Dec;57(12):2465-74. doi: 10.1007/s00125-014-3369-7. Epub 2014 Sep 17.

PMID:
25226881
11.

Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.

He T, Cooper ME.

Nat Rev Nephrol. 2014 Oct;10(10):547-8. doi: 10.1038/nrneph.2014.162. Epub 2014 Sep 9. No abstract available.

PMID:
25201141
12.

Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Fukami K, Yamagishi S, Coughlan MT, Harcourt BE, Kantharidis P, Thallas-Bonke V, Okuda S, Cooper ME, Forbes JM.

Diabetol Metab Syndr. 2014 Aug 13;6(1):86. doi: 10.1186/1758-5996-6-86. eCollection 2014.

13.

Is there a diminishing return of prior glycaemic control?

Hanssen NM, Cooper ME.

Lancet Diabetes Endocrinol. 2014 Oct;2(10):767-9. doi: 10.1016/S2213-8587(14)70160-3. Epub 2014 Jul 17. No abstract available.

PMID:
25043684
14.

Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.

Watson AM, Li J, Samijono D, Bierhaus A, Thomas MC, Jandeleit-Dahm KA, Cooper ME.

Atherosclerosis. 2014 Aug;235(2):444-8. doi: 10.1016/j.atherosclerosis.2014.05.945. Epub 2014 Jun 4.

PMID:
24945577
15.

Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes.

Tikellis C, Pickering RJ, Tsorotes D, Huet O, Cooper ME, Jandeleit-Dahm K, Thomas MC.

Diabetes. 2014 Nov;63(11):3915-25. doi: 10.2337/db13-0932. Epub 2014 May 8.

PMID:
24812427
16.

New insights into the use of biomarkers of diabetic nephropathy.

Jha JC, Jandeleit-Dahm KA, Cooper ME.

Adv Chronic Kidney Dis. 2014 May;21(3):318-26. doi: 10.1053/j.ackd.2014.03.008. Review.

PMID:
24780461
17.

Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.

Tan SM, Sharma A, Stefanovic N, Yuen DY, Karagiannis TC, Meyer C, Ward KW, Cooper ME, de Haan JB.

Diabetes. 2014 Sep;63(9):3091-103. doi: 10.2337/db13-1743. Epub 2014 Apr 16.

18.

Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis.

Koulis C, Kanellakis P, Pickering RJ, Tsorotes D, Murphy AJ, Gray SP, Thomas MC, Jandeleit-Dahm KA, Cooper ME, Allen TJ.

Clin Sci (Lond). 2014 Oct;127(7):485-97. doi: 10.1042/CS20140045.

PMID:
24724734
19.

Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.

Riphagen IJ, Deetman PE, Bakker SJ, Navis G, Cooper ME, Lewis JB, de Zeeuw D, Lambers Heerspink HJ.

Diabetes. 2014 Aug;63(8):2845-53. doi: 10.2337/db13-1652. Epub 2014 Mar 27.

20.

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

J Am Soc Nephrol. 2014 Jun;25(6):1237-54. doi: 10.1681/ASN.2013070810. Epub 2014 Feb 7.

PMID:
24511132
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk